Latest studies
- RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisKazakhstan - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisKazakhstan - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisKazakhstan - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaKazakhstan - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisKazakhstan - Active not recruitingPHASE3
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
This study looks into a new drug called elinzanetant to see if it can help women with hot flashes caused by breast cancer treatment. It compares the drug to a dummy pill to check how well it works and if it's safe.
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerHot FlashesKazakhstan - RecruitingPHASE2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called MORF-057 for adults with moderate to severe Crohn's disease. It compares different doses of the medicine to a dummy pill to see if it's safe and helps improve symptoms.
Inflammatory Bowel DiseasesCrohn's DiseaseKazakhstan - Active not recruitingPHASE3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This study compares a new drug, alectinib, with standard chemotherapy for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after surgery. We want to see if alectinib is better at stopping the cancer from coming back and if it's safe.
Carcinoma, Non-Small-Cell LungKazakhstan - Active not recruitingPHASE3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study looks at a new medicine called survodutide for people who are overweight or obese. It checks if survodutide helps with heart health problems. Participants take the medicine weekly for up to 2 years, alongside diet and exercise advice.
ObesityKazakhstan - Active not recruitingPHASE3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study looks at a new drug, pacritinib, for people with myelofibrosis and very low platelet counts. It compares pacritinib to other standard treatments decided by your doctor, to see if it can help improve symptoms.
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisKazakhstan